[go: up one dir, main page]

IE40930B1 - Decapeptides - Google Patents

Decapeptides

Info

Publication number
IE40930B1
IE40930B1 IE2036/74A IE203674A IE40930B1 IE 40930 B1 IE40930 B1 IE 40930B1 IE 2036/74 A IE2036/74 A IE 2036/74A IE 203674 A IE203674 A IE 203674A IE 40930 B1 IE40930 B1 IE 40930B1
Authority
IE
Ireland
Prior art keywords
leu
arg
tyr
glu
ser
Prior art date
Application number
IE2036/74A
Other versions
IE40930L (en
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US00402958A external-priority patent/US3855199A/en
Priority claimed from US417983A external-priority patent/US3886137A/en
Application filed by American Home Prod filed Critical American Home Prod
Publication of IE40930L publication Critical patent/IE40930L/en
Publication of IE40930B1 publication Critical patent/IE40930B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1458685 Decapeptides AMERICAN HOME PRODUCTS CORP 25 Sept 1974 [3 Oct 1973 21 Nov 1973] 41612/74 Heading C3H Peptides of Formula (I) wherein X is Ala or Leu, and the non-toxic salts thereof (hydrocholoride, hydrobromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate or ascorbate). Derivatives of (I) of Formula (II) wherein N<SP>9</SP> represents side chain nitrogen atoms of Arg, R is NH 2 , OH, O-(lower)alkyl ("lower" being C 1-6 ), O-benzyl, R<SP>1</SP> is a protecting group for the N<SP>8</SP>, N<SP>#</SP>, N<SP>#1</SP> atoms of Arg, and is nitro, tosyl, benzyloxycarbonyl or adamantyloxycarbonyl (if R<SP>1</SP> is nitro or tosyl, protection is on either the N<SP>#</SP> or N<SP>#1</SP> and, if R<SP>1</SP> is benzyloxycarbonyl or adamantyloxycarbonyl, protection is on N<SP>#</SP> and either N<SP>#</SP> or N<SP>#1</SP>); R<SP>2</SP> is a protecting group for the phenolic hydroxyl of Tyr and is acetyl, tosyl, benzoyl, t-butyl, tetrahydropyranyl, trityl, benzyl, 2,4-dichlorobenzyl or benzyloxycarbonyl; R<SP>3</SP> is a protecting group for the alcoholic hydroxyl of Ser and is one specified for R<SP>2</SP>; R<SP>4</SP> is an aminoprotecting group or hydrogen; wherein R<SP>1</SP>, R<SP>2</SP> or R<SP>3</SP> may also be hydrogen, with the proviso that at least one of R<SP>1</SP>, R<SP>2</SP> and R<SP>3</SP> is a protecting group and the non-toxic salts thereof. Derivatives of (II) of Formula (III) wherein R<SP>5</SP> is R<SP>4</SP>-(Pry)Glu, an α-aminoprotecting group or hydrogen; and A represents one of Preferred resins are benzhydrilamine, chloromethylated or hydroxymethyl styrene resins. The peptides may be prepared by Merrifield synthesis, to yield (III), followed by either (i) a one step cleavage and deprotection to yield (I) or (ii) cleavage to yield (II) followed by deprotection. Step (i) may be effected with hydrogen fluoride using benzhydrilamine resin, and step (ii) ammonolysis using a chloromethylated or hydroxymethyl resin. In the examples, the following peptides were prepared: H-(Pyr)Glu-D-Phe-Trp- Ser(Bzl) - Tyr(Bzl) - D - Ala - Leu- Arg(NO 2 ) - Pro - Gly benzhydrilamine resin; H - (Pyr)Glu - D - Phe - Trp - Ser- Tyr - D - Ala - Leu - Arg - Pro - Gly- NH 2 and acetate; H-(Pyr)Glu-D-Phe- Trp - Ser(Bzl) - Tyr(Bzl) - D - Leu- Leu - Arg(NO 2 ) - Pro - Gly benzhydrilamine resin; H - (Pyr)Glu - D - Phe - Trp- Ser - Tyr - D - Leu - Leu - Arg - Pro- Gly.NH 2 and acetate. Pharmaceutical compositions, for the inhibition of ovulation in female mammals, comprises a peptide of Formula (I) or a non-toxic salt thereof and a pharmaceutically acceptable carrier, said composition may be in unit dosage form. [GB1458685A]
IE2036/74A 1973-10-03 1974-10-01 Decapeptides IE40930B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US00402958A US3855199A (en) 1973-10-03 1973-10-03 P-glu-d-phe-t rp-ser-tyr-d-ala-leu-arg-pro-gly-nh2-and intermediates
US417983A US3886137A (en) 1973-11-21 1973-11-21 P-Glu-D-Phe-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-Gly-NH{HD 2 {B and intermediates

Publications (2)

Publication Number Publication Date
IE40930L IE40930L (en) 1975-04-03
IE40930B1 true IE40930B1 (en) 1979-09-12

Family

ID=27018102

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2036/74A IE40930B1 (en) 1973-10-03 1974-10-01 Decapeptides

Country Status (10)

Country Link
JP (1) JPS5059367A (en)
CA (1) CA1022546A (en)
CH (1) CH605676A5 (en)
DE (1) DE2447097A1 (en)
FR (1) FR2247254B1 (en)
GB (1) GB1458685A (en)
IE (1) IE40930B1 (en)
NL (1) NL7413081A (en)
NZ (1) NZ175566A (en)
PH (1) PH11571A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409208A (en) * 1980-04-15 1983-10-11 The Salk Institute For Biological Studies GnRH antagonists
DE3842010A1 (en) * 1988-12-14 1990-06-21 Hoechst Ag COMPETITIVE GONADOLIBERINE ANTAGONISTS

Also Published As

Publication number Publication date
IE40930L (en) 1975-04-03
DE2447097A1 (en) 1975-04-10
CA1022546A (en) 1977-12-13
PH11571A (en) 1978-03-31
NZ175566A (en) 1978-06-20
CH605676A5 (en) 1978-10-13
JPS5059367A (en) 1975-05-22
GB1458685A (en) 1976-12-15
NL7413081A (en) 1975-04-07
AU7352074A (en) 1976-03-25
FR2247254A1 (en) 1975-05-09
FR2247254B1 (en) 1980-01-11

Similar Documents

Publication Publication Date Title
US4689396A (en) GnRH antagonists V
EP0100218B1 (en) Gnrh antagonists
US4253997A (en) Anti-ovulatory decapeptides
US4565804A (en) GnRH Antagonists VI
CA2029678A1 (en) Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 14
US4569927A (en) GnRH Antagonists IV
CA2012480A1 (en) Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
AU3132489A (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5073624A (en) Therapeutic decapeptides
US4652550A (en) GnRH antagonists VII
EP0162575B1 (en) Gnrh antagonists vii
GB1535602A (en) Lhrh peptide derivatives
EP0063423B1 (en) Gnrh antagonists
US4619914A (en) GNRH antagonists IIIB
US4740500A (en) GnRH antagonists VIII
IE40930B1 (en) Decapeptides
US4034082A (en) Method to prevent reproduction in warm-blooded female animals with nonapeptides
GB1473020A (en) Peptides
US4377574A (en) Contraceptive treatment of male mammals
EP0038135B1 (en) Lrf antagonists
US4489061A (en) Treatment of male mammals
US5618791A (en) Memory enhancing peptides
US4386074A (en) LRF Antagonists
Erchegi et al. LH-RH antagonists: further analogs with ring-substituted aromatic residues
IE58287B1 (en) Spiro-heteroazolones for treatment of diabetes complications